AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (996.9 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

A novel oridonin analogue, CYD0682, suppresses breast cancer growth, angiogenesis, and metastasis by inhibiting the ANGPTL4/MAPK signaling axis

Xiaobin Maia,1Le Wanga,1Juan Tua,1Jialin Lia,1Jun LibYaping ZhanaPei TangaYing WangaYan WangaLingyun ZhengaQianqian ZhangaJiangchao LiaXiong LiaLijing Wanga( )Jia Zhoub( )Cuiling Qia( )
School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, China
Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, United States

Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA)

1 These authors contributed equally to this work.

Show Author Information

References

【1】
【1】
 
 
Genes & Diseases
Article number: 101681

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Mai X, Wang L, Tu J, et al. A novel oridonin analogue, CYD0682, suppresses breast cancer growth, angiogenesis, and metastasis by inhibiting the ANGPTL4/MAPK signaling axis. Genes & Diseases, 2025, 12(5): 101681. https://doi.org/10.1016/j.gendis.2025.101681

463

Views

1

Downloads

0

Crossref

1

Web of Science

1

Scopus

0

CSCD

Received: 24 July 2024
Published: 08 May 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).